Drugmaker Grifols's 'Problems Are Far From Over,' Says Oddo.

BROOKFIELD Asset Management Inc.; INVESTORS; CORPORATE reorganizations; STOCK prices; CORPORATE governance; PHARMACEUTICAL industry; DEBT relief

Grifols SA is facing challenges with financial restructuring and corporate governance issues, according to Oddo analyst Juan Ros Padilla. After Brookfield Asset Management withdrew its plans to acquire the drugmaker, Grifols needs to address high interest burdens and consider options like asset disposals, debt restructuring, and raising fresh capital. The company's stock dropped by 14% following Brookfield's announcement, highlighting ongoing concerns about corporate governance and financial stability. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)